General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Since muscle burns more calories than fat, increasing muscle mass can accelerate fat loss
For GHK-Cu skin benefits, see our GHK-Cu benefits guide
Reported applications include NNMT enzyme inhibition assays measuring 1-methylnicotinamide formation or S-adenosylhomocysteine release, intracellular target-engagement assays in differentiated 3T3-L1 adipocytes where 5-Amino-1MQ reduced intracellular 1-methylnicotinamide with an EC near 2.3 M (Neelakantan et al., Biochem Pharmacol, 2018), membrane permeability and Caco-2 transport characterisation, methyltransferase selectivity panels covering COMT, DNMT1 and PRMT3, and rodent studies of NNMT inhibition in adipose tissue and liver following the antisense knockdown work of Kraus and colleagues (Nature, 2014)
Researchers often choose this blend when studying growth hormone signaling pathways, peptide interactions, body composition mechanisms, and recovery-related biological processes
